Oral presentation delivered by Chief Medical Officer Paul Rubin, MD, at the American Diabetes Association's 84th Scientific Sessions, the world’s largest diabetes conference RICHMOND, Calif.--( BUSINESS WIRE )--BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing
Newly appointed advisors are world-renowned experts in obesity, diabetes, and cardiometabolic diseases, spanning basic biology to late-stage development RICHMOND, Calif.--( BUSINESS WIRE )--BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for
New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies RICHMOND, Calif.--( BUSINESS WIRE )--BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic
Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline Azelaprag improves metabolic and muscle function and has potential as an oral drug to significantly increase weight loss and improve
